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Summary
This paper summarizes our current stand on potential pathophysiological targets for osteoarthritis (OA) therapies. Although OA is a
complicated disease, involving the cartilage, synovial membrane, and subchondral bone, a number of interactive pathways have been found
to explain the structural changes in the disease process. Study of these three tissues has yielded a list of targets to examine for their potential
to affect disease progression. At the cartilage level, therapeutic agents, such as growth factors, could be targeted to increase chondrocyte
anabolism. At the synovial level, cytokines and cytokine receptor antagonists are potential targets for therapy. In the subchondral bone,
cytokines, growth factors and eicosanoids, and locally synthesized factors affecting bone metabolism are also potential targets of therapy.
Recent progress in the understanding of the pathophysiology of OA has led to exploration of several interesting new approaches toward the
treatment of this disease. New classes of molecules that inhibit one or more OA disease processes are under evaluation for their potential
to alter the degenerative process. The prospect of finding a cure for OA is more promising than ever. Based on the discovery of major
pathophysiological pathways leading to the structural changes observed in OA, novel ways to treat the progression of OA lesions are
emerging.
© 2003 OsteoArthritis Research Society International. Published by Elsevier Ltd. All rights reserved.
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Introduction
This presentation reviews where we stand in regard to
potential pathophysiological targets for osteoarthritis (OA)
therapies, based on our current knowledge of the disease
process.
The main development over the last few decades, as
seen by those of us who have been intimately involved in
the field of OA research, has been the change in the basic
concepts concerning the pathophysiology of the disease,
which have moved from a fairly mechanical hypothesis of
wear and tear to include a number of interactive pathways
explaining the structural changes1,2. While the disease
process is a fairly complicated one, involving three import-
ant tissues (cartilage, synovial membrane, and sub-
chondral bone), a number of pathways have now been
identified as being responsible for the different structural
changes seen during the evolution of the disease process.
There is now evidence of global cross-talking among these
tissues3, further complicating the whole process more than
one may have thought (Fig. 1).
From these three different tissues, it is possible to create
a comprehensive list of the most attractive targets to
examine for their potential to modify or stop disease pro-
gression3,4. Certainly, at the cartilage level, the agents that
could induce cartilage repair, such as growth factors, could
be targeted for their virtue of increasing the chondrocyte
anabolism. However, there is to date very limited evidence
of their potential for use in OA; thus, further investigation is
needed. At the synovial level, findings from a large number
of studies indicate that the most obvious and interest-
ing targets are the cytokines and the cytokine receptor
antagonists4.
The subchondral bone is also an interesting tissue as
a potential target for pharmacological intervention. The
reader will find in these proceedings, a number of very
interesting manuscripts on bone physiology, biochemistry,
and bone remodeling. As we have learned, during the OA
process, subchondral bone undergoes a very significant
amount of remodeling. Large numbers of cytokines and
factors synthesized locally are widely responsible for those
changes, and also may be responsible for several cross-
talking pathways between cartilage and the subchondral
bone5. These pathways could very well be participating in
cartilage destruction. One such factor, namely transform-
ing growth factor-ß (TGF-ß), has been shown to be an
extremely potent factor in upregulating the gene expression
of metalloprotease (MMP)-136 – an enzyme known to be
an important catabolic factor in OA cartilage.
Inflammation and cytokines
Among the most attractive recent findings are the data
published in a number of studies performed in the field,
including clinical studies and studies examining biological
markers, which point to an association between inflam-
mation and disease appearance and progression3,4. In fact,
there are several studies in which the levels of bio-
markers such as cartilage oligomeric matrix protein
(COMP), hyaluronic acid (HA), or c-reactive protein (CRP)
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were measured in OA patients. These studies have dem-
onstrated that there is a strong association between OA
progression and inflammation, which also constitutes a risk
factor for the development of the disease. Among those
studies, there is, in fact, one which shows a very strong
correlation between knee OA disease progression, as
estimated by arthroscopy, and the level of synovitis7.
Therefore, there seems to be less and less doubt that, at
the clinical stage of the disease, the synovial inflammation
that occurs in the OA joints is an important factor in the
progression of the disease. A number of pathways linked to
synovial inflammation or inflammation per se represent
the most interesting targets4. For instance, cytokines, such
as interleukin-1 (IL-1ß) and other pro-inflammatory
cytokines, or inflammatory factors, such as nitric oxide
(NO), (which are perhaps more than just innocent
bystanders) are responsible for the signs and symptoms of
inflammation present in OA patients8.
With respect to the cytokines, the one most talked about
in the context of OA is certainly interleukin-1 (IL-1) and, to a
lesser extent, tumor necrosis factor- (TNF-)1,2,4. IL-1 has
been a popular target in regard to the management of the
disease process for several reasons. For example, IL-1 is a
potent cartilage catabolic factor whose production or
activity can be reduced in a number of ways. For instance,
one can reduce the action of the cytokines4 at the cell level
by reducing the membrane receptor level or by using
receptor antagonists or soluble receptors. The action of
the cytokines can also be reduced by blocking certain
intracellular signaling pathways9,10.
The modulation of IL-1 activity, among other factors,
has been frequently targeted as a means for reducing
disease progression4. This is in part because a number of
tools are available to selectively inhibit IL-1, therefore,
allowing the specific measurement of its impact on the
disease process. Several in vitro studies have demon-
strated that IL-1RA (interleukin-1 receptor antagonist), the
natural receptor antagonist, is capable of reducing several
cartilage catabolic processes that are IL-1 dependent. Also,
a number of studies in different animal models have shown,
for instance, that the intra-articular injection of IL-1RA could
block the action of IL-1 and reduce disease progression11.
Recently, a number of studies using different gene transfer
methods have demonstrated that the successful in vivo
transfection of the IL-1RA gene into the OA knee joints of
dogs or rabbits could reduce the progression of OA
lesions12–14. Obviously, these are very attractive findings
that place into perspective the concept that opposing the
effect of IL-1 is an interesting potential objective for OA
therapy. However, a number of drawbacks in the use of
gene therapy remain, and a lot more work still needs to be
done. Since IL-1RA injections have proven to be effective
disease-modifying antirheumatic drug (DMARD) treatment
for rheumatoid arthritis (RA)15, it is hoped that this therapy
will soon be tested for the clinical treatment of OA. Another
interesting target in the IL-1 system, is ICE (interleukin-1
Fig. 1. Global interaction of catabolic pathways in osteoarthritic tissues, which are responsible for the structural changes of the disease.
(Reproduced with permission. Henrotin Y, Reginster J-Y. Le cartilage articulaire peut-il se re´ge´ne´rer? Le ge´ne´raliste 1988;415:11.)
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converting enzyme), which is the converting enzyme
responsible for the conversion from the proform of IL-1 into
its active (mature) form. The inhibition of ICE has been
recently shown in vitro to effectively reduce the production
of the active form of IL-1ß in OA cartilage and synovium16;
these findings provide a strong rationale for the use of ICE
inhibitors in the treatment of OA. A number of studies with
an orally active ICE inhibitor are already underway in RA
patients, and the results should soon become available.
This form of therapy certainly represents an interesting
potential treatment for OA.
Signaling pathways
Another possible way to oppose the effect of cytokine or
growth factors lies in the specific inhibition of a number of
intracellular signaling pathways. Such pathways include
the protein kinase cascades responsible for transmitting
the cell signal from the cell membrane to the nuclei, where
it induces the cell response. Obviously these kinases – the
most important of which include P38, SAPK/Jun, and
ERK-1/2 – are a most appealing target. There are already a
number of drugs under development whose mechanism of
action involves the specific inhibition of these kinases.
In a recent publication, the use of a selective P38
inhibitor was shown to reduce the progression of lesions in
a rat model of inflammatory arthritis17. One interesting
study done in our laboratory has shown that orally active
MEK-1/2 selective inhibitors could reduce the progression
of lesions in the rabbit anterior cruciate ligament (ACL)
model of OA and, as well, reduce the synthesis of catabolic
factors such as MMPs18.
Another quite interesting field of research is the develop-
ment of small molecules that can inhibit the binding of
transcription factors at the DNA level. A good example of
such inhibitors are the peroxisome-proliferator activated
receptors (PPARs), which are a family of nuclear receptors
that can inhibit the binding of a number of transcription
factors, such as NK-B and AP-1, to their target gene19.
Several very interesting studies are now underway to find
some small molecules that could inhibit the binding of
certain transcription factors to their DNA sequence on the
target gene. This will allow the specific control of the
overexpression of a number of genes that occur in many
arthritic conditions, for example OA.
Metalloproteases
Numerous studies have examined the role of MMPs in
OA1,2,20. In fact, MMPs have been at the center stage of
OA, in regard to disease modifying osteoarthritis drug
(DMOAD) therapy21. They were one of the first targets to
be explored. Today, a great deal is known about the MMP
cascade and its activation process. A number of MMPs,
Fig. 2. Schematic representation of the role of the inducible form of nitric oxide synthase (iNOS) and nitric oxide (NO) in the pathophysiology
of osteoarthritis. (Reproduced from Arthritis and Allied Conditions. A Textbook of Rheumatology, 14th edition, Baltimore, MD: Lippincott,
Williams & Wilkins, 2000; pp. 2195–2215, Figure 110.3, with permission from Lippincott, Williams & Wilkins.)
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such as MMP-13, have been selected as being more
attractive targets for the treatment of OA. Selective inhibi-
tion is preferred over broad inhibition primarily to avoid side
effects potentially related to MMP inhibition.
MMP action can be controlled in a number of ways21.
Firstly, their synthesis or the transformation of the proMMP
into active MMP can be inhibited. Also, the enzyme activity
per se could be inhibited by many means, including the use
of chemical inhibitors. These are generally chelators of
heavy metals such as zinc and calcium. Some of these
compounds have already been tested in clinical trials. From
these trials, we have learned that MMP inhibitors could
produce some significant side effects. So far, only a very
limited amount of information is available about their ability
to reduce the progression of the disease in men. A study
with doxycycline is currently underway in patients with knee
OA. This drug exerts a potent chelating effect against
heavy metals and, therefore, possesses an MMP inhibitory
activity. In addition, doxycycline can also reduce MMP gene
expression and has been proven to reduce the severity of
canine OA22. It is hoped that this trial will bring forth some
interesting findings.
Nitric oxide synthase and COX-2
(cyclooxygenase-2)
Among the different pathways involved in inflammation,
the NO pathway is interesting for at least two main reasons.
Firstly, NO and its byproducts, reactive oxygen species
(ROS), are capable of inducing the inflammatory com-
ponent of OA23. Secondly, NO is also capable of inducing
tissue damage and tissue destruction; therefore, it could be
responsible not only for the symptoms, but also for the
disease process per se23,24 (Fig. 2).
Through a number of studies, we have learned that the
inducible form nitric oxide synthase (iNOS) and the excess
production of NO in OA tissues are likely to be involved in
structural changes of OA through a number of mech-
anisms. First, NO and ROS can induce chondrocyte death
by apoptosis1,8,25. They can also stimulate the synthesis
and activities of MMPs8 and reduce the anabolism of
cartilage by inhibiting the synthesis of collagen and proteo-
glycan1. Moreover, NO is also capable of increasing the
activity of COX-2 and consequently seems responsible for
an increase in the signs and symptoms of the disease26.
Therefore, it is believed that this molecule is a most
interesting target because reducing its excess production
may reduce not only the symptoms but also the pro-
gression of disease, thus simultaneously reaching two
targets. This hypothesis is supported by a recent study in
the dog ACL model of OA in which therapeutic dosages of
a specific inhibitor of iNOS were administered orally23. The
erosions of cartilage were very significantly reduced in a
dose-dependent manner. The inhibitor also reduced the
number of chondrocytes undergoing death by apoptosis, as
well as the excess synthesis of IL-1ß and MMP produced in
the synovial membrane and cartilage23,25,26.
Additional studies have also demonstrated that the
induction of COX-2 expression and the subsequent
increase in prostaglandin (PG) production are essential for
NO-induced chondrocyte apoptosis27. Selective inhibition
of COX-2 completely blocks the apoptotic phenomenon,
which is induced by NO. This interesting link between NO
and the PG pathway also brings forward the fact that PGs
in OA may be more than just ordinary inflammatory factors.
Bone remodeling factors
Finally, we would like to highlight issues relating to
the subchondral bone. Subchondral metabolism has
been described by Lajeunesse and Burr28,29. However,
questions remain as to whether this tissue is involved in the
Fig. 3. Schematic representation of the mechanisms involved in the remodeling of osteoarthritic subchondral bone and possible interaction
with cartilage. (Reproduced from JY Reginster, JP Pelletier, J Martel-Pelletier, Y Henrotin, Eds. Osteoarthritis: Clinical and Experimental
Aspects, Heidelberg, Germany: Springer-Verlag, 1999, pp. 156–187, Fig. 2, with permission from Springer-Verlag GmbH & Co. KG.)
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appearance/progression of OA (Fig. 3)2. Some of these
questions may have been answered in a recent study in the
dog ACL model. This study has suggested some interesting
concepts concerning the structural and biochemical
changes of OA subchondral bone and has also raised new
questions that will prompt further exploration into this area
as a potential new strategy for the treatment of OA30.
In this study, we first examined the potential of a non-
steroidal anti-inflammatory drug (NSAID), carprofen, to
modify the progression of experimental OA. Second, we
examined the effect of the drug on the structural changes in
subchondral bone, and also the effect of therapeutic con-
centrations of the drug on bone cell metabolism. The
results from this study showed a dose-dependent reduction
in the progression of cartilage lesions over time. The
morphology of the subchondral plate in the OA dogs that
received no treatment presented a very high level of bone
resorption with an increased number of bone resorption
lacunae containing a large number of osteoclasts, indicat-
ing the presence of a very active remodeling process. The
cortical plate was also thinner in the OA dogs. Interestingly,
in the two groups of dogs that were treated with the NSAID,
there was a very significant reduction in the number of bone
remodeling units and bone resorption, as well as a preser-
vation of the thickness of the subchondral plate which was
similar to that seen in normal dogs.
The levels of IGF-1, urokinase plasminogen activator
(uPA), and TGF- production by osteoblasts from animals
treated with the NSAID were lower than those in untreated
OA dogs and comparable to those in normal dogs. These
data indicate that the drug can reduce in vivo the synthesis
of important factors which are likely involved in the matrix
formation and matrix remodeling of the subchondral bone.
In summary, data from this study show that under these
experimental conditions, this NSAID could induce a simul-
taneous reduction in OA structural changes seen at the
cartilage and subchondral bone level. Whether or not the
sparing effect of the drug on the remodeling of subchondral
bone is responsible for the reduction in the progression of
lesions at the cartilage level remains unanswered. To get a
clear answer to the question, we obviously will have to test
drugs that could specifically and selectively target bone
cells at the subchondral bone level.
Conclusions
Recent progress in the understanding of the patho-
physiology of OA has led to the exploration of several
interesting new approaches toward the treatment of this
disease. New classes of molecules that inhibit one or more
OA disease processes are under evaluation for their
potential to alter the degenerative process.
The prospect of finding a cure for OA is more promising
than ever. Based on the discovery of major patho-
physiological pathways leading to the structural changes
observed in OA, novel ways to treat the progression of OA
lesions are emerging.
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